A critique of the EC's expert (draft) reports on the status of alternatives for cosmetics testing to meet the 2013 deadline

Altex

Volumn 28, Issue 2, 2011, Pages 131-148

  Taylor, Katy ^a   Casalegno, Carlotta ^a   Stengel, Wolfgang ^a  

^a European Coalition to End Animal Experiments (ECEAE)   (United Kingdom)

Author keywords

Alternatives; Cosmetics; Expert report; In vitro; TTC

Indexed keywords

COSMETIC;

ANIMAL TESTING ALTERNATIVE; ANIMAL TESTING REPLACEMENT; ARTICLE; CARCINOGENICITY; CONSUMER; EXPERT SYSTEM; HEALTH CARE ORGANIZATION; IN VITRO STUDY; NONHUMAN; PREDICTION; REPEATED DOSE INFORMATION; REPRODUCTIVE TOXICITY; SKIN SENSITIZATION; THRESHOLD OF SENSITIZATION CONCERN; TOXICITY TESTING; TOXICOKINETICS; ANIMAL; ANIMAL WELFARE; EUROPEAN UNION; EXPERT WITNESS; LEGAL ASPECT; METHODOLOGY;

ANIMAL TESTING ALTERNATIVES; ANIMAL WELFARE; ANIMALS; COSMETICS; EUROPEAN UNION; EXPERT TESTIMONY;

EID: 80052873232     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: 10.14573/altex.2011.2.131     Document Type: Article

References (134)

1. Aeby, P., Ashikaga, T., Bessou-Touya, S. et al. (2010). Identifying and characterizing chemical skin sensitizers without animal testing: Colipa's research and method development program. Toxicol. In Vitro 24, 1465-1473.
2. Ahlfors, S. R., Sterner, O. and Hansson, C. (2003). Reactivity of contact allergenic haptens to amino acid residues in a model carrier peptide, and characterization of formed peptide-hapten adducts. Skin Pharmacol. Appl. Skin Physiol. 16, 59-68. (Pubitemid 36173471)
3. Andersen, M. E. (2003). Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol. Lett. 138, 9-27.
4. Anon (2008). EU FP7 Project Sens-it-iv Newsletter 13. http://www.sens-it-iv.eu/files/newsletter/Sens-it-iv-Newsletter-13.html
5. Anon (2010). Terms of reference "Report on alternative (nonanimal) methods for cosmetics testing: Current status and future prospects - 2010". European Commission, Health and Consumers Directorate-General (DG SANCO), document, no longer on the website.
6. Aptula, A. O. and Roberts, D. W. (2006). Mechanistic applicability domains for non animal-based prediction of toxicological end points: general principles and application to reactive toxicity. Chem. Res. Toxicol. 19, 1097-1105. (Pubitemid 44384841)
7. Ashikaga, T., Sakaguchi, H., Sono, S. et al. (2010). A comparative evaluation of in vitro skin sensitisation tests: The human Cell-line Activation Test (h-CLAT) versus the Local Lymph Node Assay (LLNA). ATLA 38, 275-284.
8. AXLR8 (2010). Alternative Testing Strategies Progress Report 2010. AXLR8 Consortium Report, http://www.AXLR8.eu
9. Bailey, J., Knight, A. and Balcombe, J. (2005). The future of teratology research is in vitro. Biogenic Amines 19, 97-145. (Pubitemid 40903996)
10. Bailey, J. and Taylor, K. (2009). Comment: The SCHER report on non-human primate research - biased and deeply flawed. ATLA 37, 427-435.
11. Balls, M. and Clothier, R. (2010). A FRAME response to the Draft Report on Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects-2010. ATLA 38, 345-353.
12. Bercu, J. P., Morton, S. M., Deahl, J. T. et al. (2010). In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances. Regul. Toxicol. Pharmacol. 57, 300-306.
13. Bernauer, U., Heinemeyer, G., Heinrich-Hirsch, B. et al. (2008). Exposure-triggered reproductive toxicity testing under the REACH legislation: A proposal to define significant/relevant exposure. Toxicol. Lett. 176, 68-76. (Pubitemid 50009765)
14. Blaauboer, B. J. and Andersen, M. E. (2007). The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch. Toxicol. 81, 385-387. (Pubitemid 46701597)
15. Boekelheide, K. and Campion, S. N. (2010). Toxicity testing in the 21st century: using the new toxicity testing paradigm to create a taxonomy of adverse effects. Toxicol. Sci. 114, 20-24.
16. Boobis, A. R., Cohen, S. M., Doerrer, N. G. et al. (2009). A data-based assessment of alternative strategies for identification of potential human cancer hazards. Toxicol. Pathol. 37, 714.
17. Bouvier d'Yvoire, M., Prieto, P., Blaauboer, B. J, et al. (2007). Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. ATLA 35, 661-671.
18. Bremer, S. (2008). The need for realism in reproductive toxicity testing. ATLA 36, 717.
19. Bronaugh, R. L., Stewart, R. F., Congdon, E. R. et al. (1982). Methods for in vitro percutaneous absorption studies. I. Comparison with in vivo results. Toxicol. Appl. Pharmacol. 62, 474-80. (Pubitemid 12136694)
20. Carfi, M. A., Gennari, A., Malerba, I. et al. (2007). In vitro tests to evaluate immunotoxicity: A preliminary study. Toxicol. 229, 11-22. (Pubitemid 44881160)
21. CERI (2006). Draft validation report of TA assay using HeLa-hER-9903 to detect estrogenic activity. Available at: http://www.oecd.org/dataoecd/7/27/ 37504278.pdf
22. Chaundry, Q., Piclin, N., Cotterill, J. et al. (2010). Global QSAR models of skin sensitisers for regulatory purposes. Chem. Central J. 4, S5.
23. Chiba, M., Ishi, Y. and Sugiyama, Y. (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J. 11, 262-276.
24. Combes, R., Balls, M., Curren, R. et al. (1999). Cell transformation assays as predictors of human carcinogenicity. The report and recommendations of ECVAM Workshop 39. ATLA 27, 745-767. (Pubitemid 29503028)
25. Combes, R., Balls, M., Illing, P. et al. (2006). Possibilities for a new approach to chemicals risk assessment. The report of a FRAME Workshop. ATLA 34, 621-649. (Pubitemid 46238601)
26. Combes, R. (2009). The "uEST" in vitro test for embryotoxicity - Validated and endorsed or not? Toxicol. In Vitro 23, 360-336.
27. Contrera, J. F., Kruhlak, N. L., Matthews, E. J. et al. (2007). Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul. Toxicol. Pharmacol. 49, 172-182. (Pubitemid 350103627)
28. Corvi, R., Albertini, S., Hartung, T. et al. (2008). ECVAM retrospective validation of in vitro micronucleus test (MNT). Mutagenesis 23, 271-283. (Pubitemid 351918959)
29. Dartel, D. A. M., Pennings, J. L., De la Fonteyne, L. J. et al. (2010). Monitoring developmental toxicity in the embryonic stem cell test using differential gene expression of differentiation-related genes. Toxicol. Sci. 116, 130-139.
30. Duff, T., Carter, S., Feldman, G. et al. (2002). Transepithelial resistance and inulin permeability as endpoints in in vitro nephrotoxicity testing. ATLA 30, 53-59. (Pubitemid 36168713)
31. ECVAM (2009). Statement on the performance under UN GHS of three in vitro assays for skin irritation testing and the adaptation of the reference chemicals and defined accuracy values of the ECVAM skin irritation performance standards.
32. EFSA (2007). Opinion of the scientific panel on plant protection products and their residues on a request from the Commission related to the revision of Annexes II and III to Council Directive 91/414/EEC concerning the placing of plant protection products on the market - Toxicological and metabolism studies (Question No EFSA-Q-2006-118)
33. Ennever, F. K., Noonan, T. J. and Rosenkranz, H. S. (1987). The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis. 2, 73-78. (Pubitemid 17045278)
34. Ennever, F. K. and Lave, L. B. (2003). Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul. Toxicol Pharmacol. 38, 52-57. (Pubitemid 36870870)
35. Enoch, S. J., Cronin, M. T., Schultz, T. W. et al. (2008a). Quantitative and mechanistic read across for predicting skin sensitisation potential of alkenes acting via Michael addition. Chem. Res. Toxicol. 21, 513-520.
36. Enoch, S. J., Madden, J. C. and Cronin, M. T. (2008b). Identification of mechanisms of toxic action for skin sensitisation using a SMARTS pattern based approach. SAR QSAR Environ. Res. 19, 555-578.
37. Enoch, S. J., Roberts, D. W. and Cronin, M. T. (2010). Mechanistic category formation for the prediction of respiratory sensitisation. Chem. Res. Toxicol. 23, 1547-1555.
38. ESAC (2002). Statement on the use of scientifically-validated in vitro tests for embryotoxicity. ESAC Statement 3 June 2002. http://ecvam.jrc.it/
39. ESAC (2006). Statement on the scientific validating of the in vitro micronucleaus test as an alternative to the in vitro chromosome aberration assay for genotoxicity testing. ESAC Statement 17 November 2006. http://ecvam.jrc.it/
40. Fedorowicz, A., Lingyi, Z., Harshinder, S. et al. (2008). QSAR study of skin sensitisation using local lymph node assay data. Int. J. Mol. Sci. 5, 56-66. (Pubitemid 38760916)
41. Fjodorova, N., Vračko, M., Novič, M. et al. (2010). New public QSAR model for carcinogenicity. Chemistry Central J. 4, S3.
42. Fowler, P., Smith, K., Jong, J. et al. (in press). Reduction of misleading (false) positive results in mammalian genotoxicity assays. I. Choice of cell type. Mutat Res.
43. Freyberger, A., Wilson, V., Weimer, M. et al. (2010a). Assessment of a robust model protocol with accelerated throughput for a human recombinant full length estrogen receptor- binding assay: Protocol optimization and intralaboratory assay performance as initial steps towards validation. Reprod. Toxicol. 30, 50-59.
44. Freyberger, A., Weimer, M., Lofink, W. et al. (2010b). Short-term dynamic culture of rat testicular fragments as a model to assess effects on steroidogenesis-potential use and limitations. Reprod. Toxicol. 30, 36-43.
45. Genschow, E., Spielmann, H., Scholz, G. et al. (2002). The EC-VAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. ATLA 30, 151-76. (Pubitemid 34534620)
46. Gerberick, G. F., Vassallo, J. D., Foertsch, L. M. et al. (2007). Quantification of chemical peptide reactivity for screening contact allergens: A classification tree model approach. Toxicol. Sci. 97, 417-427. (Pubitemid 47073857)
47. Goebel, C., Hewitt, N. J., Kunze, G. et al. (2009). Skin metabolism of aminophenols: Human keratinocytes as a suitable in vitro model to qualitatively predict the dermal transformation of 4-amino-2-hydroxytoluene in vivo. Toxicol. Appl. Pharmacol. 235, 114-123.
48. Gordon, J. D. and Clark, G. C. (2005). Submission of XDS's LUMI-CEL ER high-throughput system for screening estrogen- like chemicals for review by ICCVAM. http://iccvam.niehs.nih.gov/methods/endocrine/endodocs/ ICCVAMSubmission28Jan05.pdf
49. Grindon, C., Combes, R., Cronin, M. T. et al. (2008). An integrated decision-tree testing strategy for repeat dose toxicity with respect to the requirements of the EU REACH legislation. ATLA 36, 93-101. (Pubitemid 351439801)
50. Hettwer, M., Reis-Fernandes, M. A., Iken, M. et al. (2010). Metabolic activation capacity by primary hepatocytes expand the applicability of the embryonic stem cell test as an alternative to experimental animal testing. Reprod. Toxicol. 30, 13-20.
51. Hewitt, P. (2009). Predictive safety biomarkers in non-clinical development. Presentation. http://www.insightpharmareports. com/uploadedFiles/ Reports/Reports/Multiplex-Assays/Presentations/Hewitt-Phil.pdf
52. Horii, I. and Yamada, H. (2007). In vitro hepatotoxicity testing in the early phase of drug discovery. AATEX 14, Spec. Issue, 437-441.
53. Hosea, N. A., Collard, W.T., Cole, S. et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol. 49, 513-533.
54. Huang, S., Wiszniewskia, L., Derouette, J. P. et al. (2009). In vitro organ culture models of asthma. Drug Discov. Today 6, 137-144.
55. Hurtt, M., Cappon, G. D., Browning, A. et al. (2003). Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food producing animals. Food Chem. Toxicol. 41, 611-619. (Pubitemid 36349541)
56. ICCVAM (1999). The murine local lymph node assay: A test method for assessing the allergic contact dermatitis potential of chemicals/compounds. National Toxicology Program, NIH Publication No. 99-4494; http://iccvam.niehs. nih.gov/
57. Inoue, T., Tanaka, K., Mishima, M. et al. (2007). Predictive in vitro cardiotoxicity and hepatotoxicity screening system using neonatal rat heart cells and rat hepatocytes. AATEX 14, Spec. Issue, 457-462.
58. Jäckh, C., Blatz, V., Guth, K. et al. (2010). Enzyme activities for xenobiotic metabolism in human reconstructed skin models. ALTEX 27, Spec. Issue, 60.
59. Jennings, P. (2010). The role of the Nrf2 pathway in nephrotoxicity. ALTEX 27, Spec. Issue, 60.
60. Jirova, D., Basketter, D., Liebsch, M. et al. (2010). Comparison of human human skin irritation patch test data with in vitro skin irritation assays and animal data. Contact Dermatitis 62, 109-116.
61. Jones, H. M., Parrott, N., Jorga, K. et al. (2006). A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45, 511-542.
62. Keller, D., Krauledat, M. and Scheel, J. (2009). Feasibility study to support a threshold of sensitization concern concept in risk assessment based on human data. Arch. Toxicol. 83, 1049-1060.
63. Kirkland, D. and Fowler, P. (2010). Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells in vitro at concentrations exceeding 1 mM, including retesting of compounds of concern. Mutagenesis 25, 539-553.
64. Kirkland, D. M., Aardema, M., Henderson, L. et al. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and noncarcinogens I. Sensitivity, specificity and relative predictivity. Mut. Res. 7, 70.
65. Knight, A. K., Bailey J. B. and Balcombe, J. (2005). Which drugs cause cancer? Br. Med. J. 5, 477-478.
66. Kola, I. and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Rev. 3, 711-715. (Pubitemid 39173511)
67. Kroes, R., Renwick, A. G., Feron, V. et al. (2007). Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food Chem. Toxicol. 45, 2533-2562. (Pubitemid 47610800)
68. Kusama, M., Toshimoto, K., Maeda, K. et al. (2010). In silico classification of major clearance pathways of drugs based on physicochemical parameters. Drug Metab. Dispos. 38, 1362-1370.
69. La Sala, G., Farini, D., and De Felici, M. (2010). Estrogenic in vitro assay on mouse embryonic Leydig cells. Int. J. Dev. Biol. 54, 717-722.
70. Landsiedel, R., Fabian, E., Gamer, A. et al. (2010). The use of alternative methods for toxicity testing of nanomaterials. ALTEX 27, Spec. Issue, 78.
71. Langezaal, I. S., Hoffmann, S., Hartung, T. et al. (2002). Evaluation and prevalidation of an immunotoxicity test based on human whole-blood cytokine release. ATLA 30, 581-595. (Pubitemid 36168750)
72. Lankveld, D. P., van Loveren, H., Baken, K. A. et al. (2009). In vitro testing for direct immunotoxicity: State of the art. Meth. Mol. Biol. 598, 401-423.
73. Lazzari, G., Tessaro, I., Crotti, G. et al. (2008). Developmental of an in vitro test battery for assessing chemical effects on bovine germ cells under the ReProTect umbrella. Toxicol. Appl. Pharmacol. 233, 360-370.
74. LeBoeuf, R. A., Kerckaert, G. A., Aardema, M. J. et al. (1996). The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mut. Res. Fund. Mol. Mech. Mutagen. 356, 85-127. (Pubitemid 26308724)
75. Long, M. E. (2007). Predicting carcinogenicity in humans: The need to supplement animal-based toxicology. AATEX 14, Spec. Issue, 553-559.
76. Luciano, A. M., Franciosi, F., Lodde, V. et al. (2010). Transferability and inter-laboratory variability assessment of the in vitro bovine oocyte maturation (IVM) test within ReProTect. Reprod. Toxicol. 30, 81-88.
77. Malygin, V. V., Sokolov, V. B., Richardson, R. J. et al. (2003). Quantitative structure-activity relationships predict the delayed neurotoxicity potential of a series of o-alkyl-o-methylchloroformimino phenylphosphonates. J. Toxicol. Environ. Health A 66, 611-25. (Pubitemid 36428448)
78. Manga, N., Duffy, J. C., Rowe, P. H. et al. (2003). A hierarchical QSAR model for urinary excretion of drugs in humans as a predictive tool for biotransformation. QSAR Combinat. Sci. 22, 263-273. (Pubitemid 36723090)
79. th Congress on Alternatives to Animal Testing, Linz, Austria, 1-4 September 2010.
80. Maunz, A. and Helma, C. (2008). Prediction of chemical toxicity with local support vector regression and activity-specific kernels. SAR QSAR Environ. Res. 19, 413-431.
81. Mauthe, R. J., Gibson, D. P., Bunch, R. T. et al. (2001). The Syrian hamster embryo (SHE) cell transformation assay: review of the methods and results. Toxicol. Pathol. 29, 138.
82. McKim, J. M. Jr. (2010). Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Combinat. Chem. High Throughput Screen. 13, 188-206.
83. Morin, J. P., De Broe, M. E., Pfaller, W. et al. (1997). Nephrotoxicity testing in vitro: the current situation. ECVAM Nephrotoxicity Task Force Report 1. ATLA 25, 497-503. (Pubitemid 127520772)
84. Munro, I. C., Ford, R. A., Kennepohl, E, et al. (1996). Thresholds of toxicological concern based on structure-activity relationships. Drug Metab. Rev. 28, 209-217. (Pubitemid 26178332)
85. Natsch, A., Gfeller, H., Rothaupt, M. et al. (2007). Utility and limitations of a peptide reactivity assay to predict fragrance allergens in vitro. Toxicol. In Vitro 21, 1220-1226. (Pubitemid 350030873)
86. O'Brien, P. J., Irwin, W., Diaz, D. et al. (2006). High concordance of drug induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-604. (Pubitemid 44214526)
87. OECD (2004). OECD Guideline for the testing of chemicals. Skin absorption in vitro method. TG 428, Adopted 13 April 2004.
88. th version). OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 31.
89. OECD (2009). Multi-laboratory validation report of the h295r steroidogenesis assay to identify modulators of testosterone and estradiol production, No 132, Paris, France.
90. OECD (2010). Guidelines for the testing of chemicals, Section 4: Health effects. Test No. 417: Toxicokinetics.
91. Olson, H., Betton, G., Robinson, D. et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and animals. Reg. Toxicol. Pharmacol. 32, 56-67.
92. Paquette, J. A., Kumpf, S. W., Streck, R. D. et al. (2008). Assessment of the embryonic stem cell test and application and use in the pharmaceutical industry. Birth Defects Res. B Dev. Repro. Toxicol. 83, 104-111. (Pubitemid 351631344)
93. Parry, J. M., Parry, E., Phrakonkham, P. et al. (2010). Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing. Mutagenesis 25, 531-538.
94. Pauwels, M., Dejaegher, B., Vander Heyden, Y. et al. (2009). Critical analysis of the SCCNFP/SCCP safety assessment of cosmetic ingredients (2000-2006). Food Chem. Toxicol. 47, 898-905.
95. Pessina, A., Albella, B., Bueren, J. et al. (2001). Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol. In Vitro 15, 729-740. (Pubitemid 33043962)
96. Peters, A. K., Steemans, M., Hansen, E. et al. (2008a). Evaluation of the embryotoxic potency of compounds in a newly revised high throughput embryonic stem cell test. Toxicol. Sci. 105, 342-350.
97. Peters, A. K., Wouwer, G. V., Weyn, B. et al. (2008b). Automated analysis of contractility in the embryonic stem cell test, a novel approach to assess embryotoxicity. Toxicol. In Vitro 22, 1948-1956.
98. Poulin, P. and Theil, F. P. (2002). Predictions of pharmacokinetics prior to in vivo studies: I. Mechanism based prediction of volume if distribution. J. Pharm. Sci. 91, 129-156. (Pubitemid 34074473)
99. Prieto, P., Baird, A. W., Blaauboer, B. J. et al. (2006). The assessment of repeated dose toxicity in vitro: a proposed approach. The Report and Recommendations of ECVAM Workshop 56. ATLA 34, 315-341. (Pubitemid 44105846)
100. Python, F., Goebel, C. and Aeby, P. (2007). Assessment of the U937 cell line for the detection of contact allergens. Toxicol. Appl. Pharmacol. 220, 113-124. (Pubitemid 46507571)
101. Roberts, D. W. and Aptula, A. O. (2008). Determinants of skin sensitisation potential. J. Appl. Toxicol. 28, 377-387. (Pubitemid 351518126)
102. Roberts, D. W. and Patlewicz, G. Y. (2010). Updating the skin sensitization in vitro data assessment paradigm in 2009 - a chemistry and QSAR perspective. J. Appl. Toxicol. 30, 286-288; discussion 289.
103. Rogiers, W. and Pauwels, M. (2008). Safety assessment of cosmetics in Europe. Current Problems in Dermatology 36. Basel, Switzerland: S. Karger.
104. Russell, W. and Burch, R. (1959). The principles of humane experimental technique. London, UK: Methuen.
105. Sakaguchi, H., Ashikaga, T., Miyazawa, M. et al. (2009). The relationship between CD86/CD54 expression and THP-1 cell viability in an in vitro skin sensitization test - human cell line activation test (h-CLAT). Cell Biol. Toxicol. 25, 109-126.
106. SCCNFP (1999). Final: basic criteria for the in vitro assessment of percutaneous absorption of cosmetic ingredients, adopted by the SCCNFP, 23 June 1999, SCCNFP/0167/99.
107. th plenary meeting of 3 May 2000. http://ec.europa.eu/health/scientific-committees/consumer-safety/opinions/ sccnfp-opinions-97-04/sccp-out114-en.htm
108. SCCP (2006). Notes of guidance for the testing of cosmetic ingredients and their safety evaluation, sixth revision. SC-CP/1005/06.
109. Schaafsma, G., Kroese, E. D., Tielemans, E. L. et al. (2009). REACH, non-testing approaches and the urgent need for a change in mind set. Regul. Toxicol. Pharmacol. 53, 70-80.
110. Schäfer-Korting, M., Bock, U., Diembeck, W. et al. (2008). The use of reconstructed human epidermis for skin absorption testing: Results of the validation study. ATLA 36, 161-187. (Pubitemid 351861001)
111. Schenk, B., Weimer, M., Bremer, S. et al. (2010). The ReProTect feasibility study, a novel comprehensive in vitro approach to detect reproductive toxicants. Reprod. Toxicol. 30, 200-218.
112. Schmelzer, E., Mutig, K., Schrade, P. et al. (2009). Effect of human patient plasma ex vivo treatment on gene expression and progenitor cell activation of primary human liver cells in multi-compartment 3D perfusion bioreactors for extra-corporeal liver support. Biotechnol. Bioeng. 103, 817-827.
113. Schwengberg, S., Kettenhofen, R., Bohlen, H. et al. (2004). Predictive in vitro assays for cardiotoxicity and myelotoxicity of kinase inhibitors. Poster http://www.axiogenesis.com/cms/upload/applications/Downloads/Poster/ 090604-poster-WPC-TKI.pdf
114. th Amendment to the Cosmetics Directive (Council Directive 76/768/EEC). Brussels, 1.10.2004, 1210.
115. Selderslaghs, I. W., van Rompay, A. R., De, C. W. et al. (2009). Development of a screening assay to identify teratogenic and embryotoxic chemicals using the zebrafish embryo. Reprod. Toxicol. 28, 308-320.
116. Sonneveld, E., Riteco, J. A., Jansen, H. J. et al. (2006). Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities. Toxicol. Sci. 89, 173-187. (Pubitemid 43013766)
117. Sonneveld, E., Pieterse, B., Schoonen, W. G. et al. (2011). Validation of in vitro screening models for progestagenic activities: Inter-assay comparison and correlation with in vivo activity in rabbits. Toxicol. In Vitro 25, 545-554.
118. Søsted, H., Basketter, D. A., Estrada, E. et al. (2004). Ranking of hair dye substances according to predicted sensitization potency: quantitative structure-activity relationships. Contact Dermatitis 51, 241-254. (Pubitemid 40037048)
119. Spanhaak, S., Cook, D., Barnes, J. et al. (2008). Species concordance for liver injury: from the safety intelligence program board (6pp.). Cambridge, UK: BioWisdom, Ltd. http://www.biowisdom.com/files/SIP-Board-Species-Concordance. pdf (accessed 24.08.09).
120. Speit, G. (2009). How to assess the mutagenic potential of cosmetic products without animal tests? Mutat. Res. 678, 108-112.
121. Spielmann, H., Genschow, E., Brown, N. A. et al. (2004). Validation of the rat limb bud micromass test in the international ECVAM validation study on three in vitro embryotoxicity tests. ATLA 32, 245-274. (Pubitemid 39517738)
122. Spielmann, H. (2009). The way forward in reproductive/developmental toxicity testing. ATLA 37, 641-656.
123. Spielmann, H. (2010). Editorial: The EU Commission's Draft Report on alternative (nonanimal) methods for cosmetics testing: Current status and future prospects - 2010: A missed opportunity. ATLA 38, 339-343.
124. Sreejit, P., Kumar, S. and Verma, R. S. (2008). An improved protocol for primary culture of cardiomyocyte from neonatal mice. In Vitro Cell. Devel. Biol. - Anim. 44, 45-50.
125. Tilaoui, L., Schilter, B., Tran, L.-A. et al. (2007). Integrated computational methods for prediction of the lowest observable adverse effect level of food-borne molecules. QSAR Combinat. Sci. 26, 102-108. (Pubitemid 46202942)
126. van der Burg B., Winter, R., Man, H. Y. et al. (2010). Optimization and prevalidation of the in vitro AR CALUX method to test androgenic and antiandrogenic activity of compounds. Reprod. Toxicol. 30, 18-24.
127. Weed, D. (2005). Weight of evidence: a review of concept and methods. Risk Anal. 25, 1545-1557.
128. West, P. R., Weir, A. M., Smith, A. M. et al. (2010). Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 247, 18-27.
129. Westmoreland, C., Carmichael, P., Dent, M. et al. (2010). Assuring safety without animal testing: Unilever's ongoing research programme to deliver novel ways to assure consumer safety. ALTEX 27, 61-65.
130. Witters, H., Freyberger, A., Smits, K. et al. (2010). The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably transfected estrogen sensitive MELN cell line: Results of test performance and transferability. Reprod. Toxicol. 30, 60-72.
131. Yamazaki, S., Skaptason, J., Romero, D. et al. (2011). Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one compartment model. Drug Metab. Dispos. 39, 383-393.
132. Zeiger, E. (1998). Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance. Regul. Toxicol. Pharmacol. 28, 85-95.
133. Zeilinger, K., Schreiter, T., Darnell, M. et al. (2011). Scaling down of a clinical three- dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng. Part C Methods, Epub ahead of print, doi: 10.1089/ten.tec.2010.0580.
134. Zuang, V., Barroso, J., Bremer, S. et al. (2010). ECVAM technical report on the status of alternative methods for cosmetics testing (2008-2009). EUR 24413 EN - 2010.